35,900 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Andra AP fonden

Andra AP fonden purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the third quarter, HoldingsChannel reports. The institutional investor purchased 35,900 shares of the pharmaceutical company’s stock, valued at approximately $14,060,000.

Other institutional investors also recently modified their holdings of the company. Banco Santander S.A. grew its stake in Vertex Pharmaceuticals by 13.1% in the 3rd quarter. Banco Santander S.A. now owns 79,406 shares of the pharmaceutical company’s stock worth $31,099,000 after buying an additional 9,218 shares in the last quarter. R Squared Ltd purchased a new position in Vertex Pharmaceuticals in the third quarter worth $658,000. Integrated Advisors Network LLC increased its stake in Vertex Pharmaceuticals by 37.1% in the third quarter. Integrated Advisors Network LLC now owns 2,851 shares of the pharmaceutical company’s stock valued at $1,117,000 after acquiring an additional 771 shares during the last quarter. DNB Asset Management AS raised its position in Vertex Pharmaceuticals by 9.8% during the third quarter. DNB Asset Management AS now owns 95,414 shares of the pharmaceutical company’s stock valued at $37,368,000 after purchasing an additional 8,483 shares in the last quarter. Finally, Hohimer Wealth Management LLC raised its position in Vertex Pharmaceuticals by 54.0% during the third quarter. Hohimer Wealth Management LLC now owns 3,269 shares of the pharmaceutical company’s stock valued at $1,280,000 after purchasing an additional 1,146 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Leerink Partners increased their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. Canaccord Genuity Group upped their price target on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the company a “hold” rating in a research report on Tuesday, February 17th. Morgan Stanley reiterated an “overweight” rating and issued a $570.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Oppenheimer raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price for the company in a research note on Friday, February 13th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $542.00.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Insider Buying and Selling

In related news, EVP Jonathan Biller sold 945 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $459,600.75. Following the completion of the transaction, the executive vice president directly owned 13,659 shares of the company’s stock, valued at $6,643,054.65. This trade represents a 6.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Duncan Mckechnie sold 4,910 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the sale, the executive vice president directly owned 17,559 shares in the company, valued at $8,562,646.35. The trade was a 21.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 168,937 shares of company stock valued at $77,879,922 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 3.5%

NASDAQ:VRTX opened at $496.83 on Friday. The firm’s fifty day simple moving average is $466.55 and its 200 day simple moving average is $431.98. The stock has a market cap of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.98 EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.